Experimental Hematology
Volume 38, Issue 10 , Pages 868-876.e1 , October 2010

Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia

Received 13 January 2010 ,Revised 13 June 2010 ,Accepted 15 June 2010.

References 

  1. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(Suppl):S4–S10
  2. Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis. 2007;13:1016–1023
  3. Barillé S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-α complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw. 2000;11:546–551
  4. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9:4653–4665
  5. Nakashima K, Taga T. gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities. Semin Hematol. 1998;35:210–221
  6. Pang L, Weiss MJ, Poncz M. Megakaryocyte biology and related disorders. J Clin Invest. 2005;115:3332–3338
  7. Zheng C, Yang R, Han Z, Zhou B, Liang L, Lu M. TPO-independent megakaryocytopoiesis. Crit Rev Oncol Hematol. 2008;65:212–222
  8. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227–236
  9. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25:241–253
  10. Müllberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993;23:473–480
  11. Mullberg J, Durie FH, Otten-Evans C, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol. 1995;155:5198–5205
  12. Matthews V, Schuster B, Schütze S, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem. 2003;278:38829–38839
  13. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med. 1999;189:599–604
  14. Mitsuyama K, Sata M, Rose-John S. Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev. 2006;17:451–461
  15. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112:2190–2198
  16. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  17. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790
  18. Levine RL, Wadleugh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  19. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–3476
  20. Marta R, Goette N, Lev P, et al. Increased levels of plasma interleukin-6 soluble receptor in patients with essential thrombocythemia. Haematologica. 2004;89:657–663
  21. Murphy S, Peterson P, Iland H, Laszlo J. Experience of Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 1997;34:29–39
  22. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–2168
  23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159
  24. Nakanishi H, Yoshioka K, Joyama S, et al. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. Am J Pathol. 2004;165:471–480
  25. Jones SA, Horiuchi S, Novick D, Yamamoto N, Fuller GM. Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur J Immunol. 1998;28:3514–3522
  26. Murakami-Mori K, Taga T, Kishimoto T, Nakamura S. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi’s sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth. Int Immunol. 1996;8:595–602
  27. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O’Donnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol. 2007;171:315–325
  28. Sui X, Tsuji K, Ebihara Y, et al. Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (gp)130 signaling. Blood. 1999;93:2525–2532
  29. Marta RF, Goette NP, Molinas FC. Megakaryopoietic cytokine levels in patients with essential thrombocythemia and their relationship with clinical and biochemical features. Medicina. 2006;66:540–546
  30. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001;15:43–58
  31. Gallea-Robache S, Morand V, Millet S, et al. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine. 1997;9:340–346
  32. Briso EM, Dienz O, Rincon M. Soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008;180:7102–7106
  33. Horiuchi S, Yamamoto N, Dewan MZ, et al. Human T-cell leukemia virus type-I Tax induces expression of interleukin-6 receptor (IL-6R): shedding of soluble IL-6R and activation of STAT3 signaling. Int J Cancer. 2006;119:823–830
  34. Bauer J, Bauer TM, Kalb T, et al. Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression in human hepatocytes. J Exp Med. 1989;170:1537–1549
  35. Labbaye C, Spinello I, Quaranta MT, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol. 2008;10:788–801
  36. Varghese JN, Moritz RL, Lou MZ, et al. Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain. Proc Natl Acad Sci U S A. 2002;99:15959–1564
  37. Waetzig GH, Chalaris A, Rosenstiel P, et al. N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem. 2010;285:1781–1789
  38. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169–175
  39. Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC, et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol. 2008;87:269–276
  40. Rameshwar P, Chang VT, Gascón P. Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol. 1996;93:22–29

PII: S0301-472X(10)00242-0

doi: 10.1016/j.exphem.2010.06.007

Experimental Hematology
Volume 38, Issue 10 , Pages 868-876.e1 , October 2010

Article Tools

* Image Usage & Resolution